Noxopharm Limited
NOXOF · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $6 | $5 | $6 |
| % Growth | -60.1% | 10.7% | -3.2% | – |
| Cost of Goods Sold | $3 | $0 | $0 | $0 |
| Gross Profit | -$1 | $6 | $5 | $5 |
| % Margin | -22.3% | 97.4% | 95.2% | 95.3% |
| R&D Expenses | $3 | $11 | $8 | $7 |
| G&A Expenses | $1 | $5 | $6 | $6 |
| SG&A Expenses | $4 | $5 | $7 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | $0 | $2 | -$3 | $0 |
| Operating Expenses | $7 | $16 | $15 | $14 |
| Operating Income | -$8 | -$17 | -$15 | -$15 |
| % Margin | -313.9% | -276.1% | -280.1% | -260.5% |
| Other Income/Exp. Net | $4 | $6 | -$1 | $19 |
| Pre-Tax Income | -$4 | -$21 | -$24 | -$8 |
| Tax Expense | $0 | -$6 | -$5 | $1 |
| Net Income | -$4 | -$15 | -$19 | -$9 |
| % Margin | -149.1% | -250.5% | -343.9% | -166.7% |
| EPS | -0.012 | -0.052 | -0.064 | -0.035 |
| % Growth | 76.3% | 19.7% | -81.1% | – |
| EPS Diluted | -0.012 | -0.052 | -0.064 | -0.035 |
| Weighted Avg Shares Out | 292 | 292 | 291 | 264 |
| Weighted Avg Shares Out Dil | 292 | 292 | 291 | 264 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$15 | -$15 | -$14 |
| % Margin | -191.6% | -246.3% | -275.3% | -255.8% |